Startseite Kongressberichte & Archiv 2021 ASCO Annual Meeting Urogenital Cancer Genitourinary Cancer—Prostate, Testicular, and Penile

Genitourinary Cancer—Prostate, Testicular, and Penile

Karim Fizazi, Xavier Maldonado, Stéphanie Foulon, et al.
The study authors conclude, that adding abiraterone to androgen deprivation therapy plus docetaxel significantly improves radiographic progression-free survival in men with de novo metastatic prostate cancer. There is about 2.5 years of absolute benefit in medians. No meaningful additional short-term toxicity was observed. Clinical trial information: NCT01957436
Neeraj Agarwal, Catherine Tangen, Maha H. A. Hussain, et al.
The study authors conclude, that the improvement in overall survival did not meet the pre-specified criteria for statistical significance. The median overall survival of 70 months in the control arm with standard androgen deprivation therapy was higher than that reported in contemporary phase 3 trials in this setting, and 16 months higher than originally estimated. This trial sets a new landmark for survival estimates when patients with metastatic hormone-sensitive prostate cancer have access to multiple approved subsequent life-prolonging therapies. Clinical trial information: NCT01809691
Silke Gillessen, Ananya Choudhury, Alejo Rodriguez-Vida, et al.
The study authors confirm with the updated safety analysis the early fracture rate results. In the absence of bone-protecting agents (BPA), the risk of fracture is increased when RA223 is added to enzalutamide. The risk remains almost abolished by a preventive continuous administration of BPA in both arms. According to the study authors, this stresses the importance of complying with international recommendations in terms of giving BPA to asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer patients. Clinical trial information: NCT02194842
Smruthy Sivakumar, Jessica Kim Lee, Jay A. Moore, et al.
The study authors conclude, that there were largely similar rates of actionable gene alterations across ancestry. Men of African ancestry were less likely to receive comprehensive genomic profiling earlier in their treatment course, and less likely to be treated on clinical trials, which could impact the genomic landscape, outcomes, and ultimately disparities.
Edmund Qiao, Nikhil V. Kotha, Vinit Nalawade, et al.
The study authors conclude, that In this large national cohort of African-American men aged 40 to 55 years, PSA screening increased intensity was associated with decreased risk of lethal disease and metastases at the time of diagnosis and decreased prostate cancer-specific mortality. PSA screening and early prostate cancer detection may improve outcomes in younger African-American men.
Kosj Yamoah, Jasreman Dhillon, Peter A. Johnstone,  et al.
The study authors conclude, that clinical NCCN risk classification is an inadequate surrogate of tumor biology. It offers suboptimal risk stratification for African American men with prostate cancer. Integration of patient-specific genomic classifier into the standard of care will improve accuracy in disease risk classification and treatment recommendations for African American men. Clinical trial information: NCT02723734
Ragnhild Hellesnes, Tor Åge Myklebust, Sophie D. Fossa, et al.
The study authors conclude, that testicular cancer treatment with previous platinum-based chemotherapy or radiotherapy is associated with significantly increased long-term non-testicular cancer mortality. Non-testicular second cancer is the most important cause of death. Significantly elevated risks for non-testicular cancer mortality were observed after four or more previous platinum-based chemotherapy cycles after over 10 years of follow-up.
Noah Hunter Richardson, Sandra K. Althouse, Ryan Ashkar, et al.
The study authors conclude, that most patients with chemo-exposed late relapse will be diagnosed with an elevated AFP. Germ cell tumors patients require lifetime follow-up with an annual physical exam and tumor markers. Surgical resection, when feasible, remains the authors preferred treatment for chemo-exposed late relapse. Chemotherapy alone offers only brief responses. Patients with chemo-naïve late relapse have a more chemo-sensitive biology.